AR042152A1 - Uso de los compuestos 2,5 dihidroxibencesulfonicos para la fabricacion de un medicamento para pacientes diabeticos - Google Patents

Uso de los compuestos 2,5 dihidroxibencesulfonicos para la fabricacion de un medicamento para pacientes diabeticos

Info

Publication number
AR042152A1
AR042152A1 ARP030104411A ARP030104411A AR042152A1 AR 042152 A1 AR042152 A1 AR 042152A1 AR P030104411 A ARP030104411 A AR P030104411A AR P030104411 A ARP030104411 A AR P030104411A AR 042152 A1 AR042152 A1 AR 042152A1
Authority
AR
Argentina
Prior art keywords
manufacture
compounds
diabetic patients
dihydroxibencesulphonic
medicinal product
Prior art date
Application number
ARP030104411A
Other languages
English (en)
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of AR042152A1 publication Critical patent/AR042152A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Reproductive Health (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Uso de los componentes 2,5-dihidroxibencenosulfónicos para la fabricación de un medicamento para ser administrado por via oral destinado a la regulación de la síntesis del óxido nítrico (ON) y/o regulación del FHDE (factor hiperpolarizador derivado del endotelio) en el endotelio de pacientes diabéticos, administrándose el medicamento a una dosis diaria de <500 mg de compuestos 2,5-dihidroxibencenosulfónicos. Se utiliza para tratar retinopatias, disfunción eréctil, trastornos renales y de microcirculación coronaria, entre otros.
ARP030104411A 2002-11-29 2003-12-01 Uso de los compuestos 2,5 dihidroxibencesulfonicos para la fabricacion de un medicamento para pacientes diabeticos AR042152A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200202755A ES2208124B1 (es) 2002-11-29 2002-11-29 Uso de los compuestos 2,5-dihidroxibencenosulfonicos para la fabricacion de un medicamento.

Publications (1)

Publication Number Publication Date
AR042152A1 true AR042152A1 (es) 2005-06-08

Family

ID=32405966

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP030104411A AR042152A1 (es) 2002-11-29 2003-12-01 Uso de los compuestos 2,5 dihidroxibencesulfonicos para la fabricacion de un medicamento para pacientes diabeticos

Country Status (13)

Country Link
US (1) US20060135611A1 (es)
EP (1) EP1596850A1 (es)
JP (1) JP2006509778A (es)
CN (1) CN1744891A (es)
AR (1) AR042152A1 (es)
AU (1) AU2003289914A1 (es)
BR (1) BR0316134A (es)
CA (1) CA2507750A1 (es)
ES (1) ES2208124B1 (es)
MX (1) MXPA05005719A (es)
NO (1) NO20053032L (es)
RU (1) RU2005120634A (es)
WO (1) WO2004050075A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20070115918A (ko) * 2005-01-31 2007-12-06 교린 세이야꾸 가부시키 가이샤 멀티플 유닛형 경구 서방성 제제 및 그 제조방법
FR2902096B1 (fr) * 2006-06-13 2011-03-18 Rhodia Recherches & Tech Procede de preparation de dihydroxybenzenedisulfonates metalliques
US9198886B2 (en) * 2006-08-16 2015-12-01 Pedro Cuevas Sánchez Use of 2,5-dihydroxybenzene for the treatment of ocular diseases
US20080182513A1 (en) * 2007-01-29 2008-07-31 Hassan Amer A High Frequency Communications
CN102038671B (zh) * 2010-06-29 2012-07-04 辽宁思百得医药科技有限公司 包含左卡尼汀和羟苯磺酸盐的药物组合物
CN114601816B (zh) * 2021-10-09 2022-09-02 北京惠之衡生物科技有限公司 一种羟苯磺酸钙胶囊组合物及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2608045B1 (fr) * 1986-12-12 1990-03-02 Chauvin Laboratoires Utilisation d'inhibiteurs de xanthine- oxydase, de piegeurs de radicaux libres oxygenes et de chelateurs du fer pour la fabrication d'une composition pharmaceutique destinee au traitement du glaucome et compositions pharmaceutiques destinees au traitement du glaucome
FR2656525A1 (fr) * 1989-12-29 1991-07-05 Delalande Sa Formes d'administration de medicament a liberation controlee et leur procede de fabrication.
DE4413350A1 (de) * 1994-04-18 1995-10-19 Basf Ag Retard-Matrixpellets und Verfahren zu ihrer Herstellung
JP2000508308A (ja) * 1996-04-03 2000-07-04 ラボラトリオス デル ドクトール エステベ，エス．アー． 内皮機能の正常化、性的機能障害、糖尿病の血管合併症及び内皮起源の血管障害の治療用の医薬の製造のための２，５―ジヒドロキシベンゼンスルホン酸誘導体の使用
DE20023135U1 (de) * 2000-04-03 2003-04-03 Beisel Guenther Mittel mit verbesserter Retardwirkung

Also Published As

Publication number Publication date
US20060135611A1 (en) 2006-06-22
NO20053032L (no) 2005-06-20
JP2006509778A (ja) 2006-03-23
CA2507750A1 (en) 2004-06-17
EP1596850A1 (en) 2005-11-23
WO2004050075A1 (en) 2004-06-17
BR0316134A (pt) 2005-10-11
ES2208124B1 (es) 2005-10-01
AU2003289914A1 (en) 2004-06-23
ES2208124A1 (es) 2004-06-01
MXPA05005719A (es) 2005-08-16
RU2005120634A (ru) 2006-03-27
CN1744891A (zh) 2006-03-08

Similar Documents

Publication Publication Date Title
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
AR033444A1 (es) Forma solida de dosificacion util para la administracion oral de un compuesto activo de nicotina, a traves de la mucosa y uso de un compuesto activo de nicotina para prepararla
AR022085A1 (es) Una forma de dosificacion farmaceutica de liberacion sostenida y una tableta comprimida
NO20055880L (no) Memantin orale doseringsformer
WO2005065069A3 (en) Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer&#39;s disease
BR9909672A (pt) uso de um composto medicinal ativo no preparo de um medicamento para o tratamento de hipertensão
CO5170471A1 (es) Tabletas de liberacion modificada que incluyen amoxilina y clavulanato de potasio
RU2010105122A (ru) Композиции для ухода за полостью рта, продукты и способы применения
DE602004032149D1 (de) Oros-push-stick für die kontrollierte abgabe von wirkstoffen
ES2542842T3 (es) Composición que comprende taurolidina y/o taurultam para el tratamiento del cáncer
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
DE50203456D1 (de) Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel
AR019053A1 (es) Uso de 2&#39;2&#39;-difluoronucleosidos para la preparacion de un medicamento y composicion farmaceutica y producto farmaceutico que los contienen
AR030039A1 (es) Composicion farmaceutica que comprende una droga inhibidora selectiva de la ciclooxigenasa-2, su uso en la fabricacion de un medicamento para tratar o prevenir afecciones mediadas por la ciclooxigenasa-2 y metodo para hacer dicho medicamento
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
AR035946A1 (es) Composiciones farmaceuticas estrogenicas para usar en el tratamiento de desordenes en mujeres perimenopausicas, menopausicas o posmenopausicas, y usos de dichas composiciones para la preparacion de medicamentos
CO5690570A2 (es) Nueva combinacion sinergistica que comprende roflumilast y formoterol
AR036312A1 (es) Composicion farmaceutica
AR042153A1 (es) Uso de los compuestos 2,5- dihidroxibencenosulfonicos para la fabricacion de un medicamento
ES2119748T3 (es) Composicion farmaceutica que contiene un farmaco ligeramente soluble en agua.
AR042152A1 (es) Uso de los compuestos 2,5 dihidroxibencesulfonicos para la fabricacion de un medicamento para pacientes diabeticos
CO5251425A1 (es) Metodo y composiciones para administrar taxanos oralmente a pacientes humanos
UY25798A1 (es) Composición farmacéutica de liberación modificada que comprende un sensibilizador de insulina tiazolidinadiónico.
AR037356A1 (es) Forma de dosificacion oral de una prodroga de sulfonamida

Legal Events

Date Code Title Description
FA Abandonment or withdrawal